S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Completed · Phase 1

Conditions studied: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Lapatinib and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Everolimus may also stop the growth of cancer cells by blocking blood flow to the cancer. Giving lapatinib together with everolimus may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib and everolimus in treating patients with advanced solid tumors or non-Hodgkin's lymphoma.

Key facts

Study ID

NCT00352443

Run by

SWOG Cancer Research Network

People needed

66

Starts

2006-09-01

Expected to finish

2013-09-01

Last updated by the study team

2015-03-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
• University of California Davis Cancer Center — Sacramento, California, United States
• University of Colorado Cancer Center at UC Health Sciences Center — Aurora, Colorado, United States
• Lucille P. Markey Cancer Center at University of Kentucky — Lexington, Kentucky, United States
• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
• University Cancer Center at University of Washington Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.